MedTrace Logo

A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants

NCT04320745 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2022-07-12

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effect of a once daily Androderm® dose on Blood Pressure (BP) in adult hypogonadal men as measured by 24-hour ABPM.

Conditions

  • Hypogonadism

Interventions

DRUG

Androderm®

Androderm® transdermal dose.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Anna Chan · Allergan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-19
Primary Completion
2021-06-24
Completion
2021-06-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04320745 on ClinicalTrials.gov